Ionis Pharmaceuticals IONS Proceeds From Sale And Maturity Of Available For Sale Securities
Proceeds From Sale And Maturity Of Available For Sale Securities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's proceeds from sale and maturity of available for sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
- Ionis Pharmaceuticals (IONS) reported proceeds from sale and maturity of available for sale securities of $752.82M in Q1 2026.
- How has Ionis Pharmaceuticals's proceeds from sale and maturity of available for sale securities changed year-over-year?
- Ionis Pharmaceuticals's proceeds from sale and maturity of available for sale securities increased by 52.2% year-over-year, from $494.76M to $752.82M.
- What is the long-term trend for Ionis Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's proceeds from sale and maturity of available for sale securities has grown at a 6.0% compound annual growth rate (CAGR), from $1.34B to $1.7B.